BidaskClub cut shares of BioScrip (NASDAQ:BIOS) from a buy rating to a hold rating in a report released on Friday.
Several other equities research analysts have also weighed in on BIOS. SunTrust Banks reiterated a buy rating and set a $3.00 price objective on shares of BioScrip in a research note on Friday, November 3rd. Zacks Investment Research lowered shares of BioScrip from a hold rating to a sell rating in a research note on Tuesday, November 7th. Finally, ValuEngine upgraded shares of BioScrip from a strong sell rating to a sell rating in a research note on Thursday, November 9th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and an average price target of $3.63.
Shares of BioScrip (BIOS) opened at $2.93 on Friday. BioScrip has a 12 month low of $1.35 and a 12 month high of $3.39. The company has a quick ratio of 1.60, a current ratio of 1.91 and a debt-to-equity ratio of -6.11.
Several large investors have recently made changes to their positions in BIOS. Dynamic Technology Lab Private Ltd acquired a new stake in shares of BioScrip in the third quarter valued at approximately $114,000. Gotham Asset Management LLC acquired a new stake in shares of BioScrip in the fourth quarter valued at approximately $114,000. Voya Investment Management LLC increased its stake in shares of BioScrip by 41.4% in the second quarter. Voya Investment Management LLC now owns 50,799 shares of the company’s stock valued at $138,000 after purchasing an additional 14,867 shares during the period. Highbridge Capital Management LLC acquired a new stake in shares of BioScrip in the third quarter valued at approximately $153,000. Finally, MetLife Investment Advisors LLC acquired a new stake in shares of BioScrip in the fourth quarter valued at approximately $174,000. Institutional investors own 85.51% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/19/bioscrip-bios-lowered-to-hold-at-bidaskclub.html.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.